{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:34:05Z","timestamp":1787625245746,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873156"],"award-info":[{"award-number":["81873156"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000075"],"award-info":[{"award-number":["82000075"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Natural Science Foundation of Liaoning","award":["2020-BS-195"],"award-info":[{"award-number":["2020-BS-195"]}]},{"name":"Liaoning Province Education Foundation","award":["LZ2019051"],"award-info":[{"award-number":["LZ2019051"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuroendocrine tumors (NETs) arise from neuroendocrine cells and are extremely rare in the biliary tract. Currently, there are no guidelines for the diagnosis and treatment of biliary NETs. We presented a case with NETs G1 of the hilar bile duct and the challenges for her treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 24-year-old woman was presented to our department with painless jaundice and pruritus, and the preoperative diagnosis was Bismuth type II hilar cholangiocarcinoma. She underwent Roux-en-Y hepaticojejunostomy with excision of the extrahepatic biliary tree and radical lymphadenectomy. Unexpectedly, postoperative pathological and immunohistochemical examination indicated a perihilar bile duct NETs G1 with the microscopic invasion of the resected right hepatic duct. Then the patient received 3 cycles of adjuvant chemotherapy (Gemcitabine and tegafur-gimeracil-oteracil potassium capsule). At present, this patient has been following up for 24\u00a0months without recurrence or disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We know little of biliary NETs because of its rarity. There are currently no guidelines for the diagnosis and treatment of biliary NETs. We reported a case of perihilar bile duct NETs G1 with R1 resection, as far as we know this is the first report. More information about biliary NETs should be registered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-021-02019-6","type":"journal-article","created":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T15:02:42Z","timestamp":1641654162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Challenges in treatment of a patient suffering from neuroendocrine tumor G1 of the hilar bile duct: a case report"],"prefix":"10.1186","volume":"22","author":[{"given":"Biao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingkai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,8]]},"reference":[{"issue":"6","key":"2019_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3322\/caac.21493","volume":"68","author":"M Cives","year":"2018","unstructured":"Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018;68(6):471\u201387.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"2019_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342.","journal-title":"JAMA Oncol"},{"issue":"3","key":"2019_CR3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.4103\/ijem.IJEM_446_17","volume":"22","author":"CD Del Arco","year":"2018","unstructured":"Del Arco CD, Sastre J, Peinado P, Diaz A, Medina LO, Fernandez Acenero MJ. Neuroendocrine neoplasms in rare locations: clinicopathological features and review of the literature. Indian J Endocrinol Metab. 2018;22(3):308\u201315.","journal-title":"Indian J Endocrinol Metab"},{"issue":"2","key":"2019_CR4","first-page":"641","volume":"58","author":"AI Costin","year":"2017","unstructured":"Costin AI, P\u0103un I, P\u0103un M, Constantin VD, V\u00e2rcu\u015f F. Primary neuroendocrine tumors\u2014an extremely rare cause of obstruction of extrahepatic bile ducts: a case report. Rom J Morphol Embryol. 2017;58(2):641\u20134.","journal-title":"Rom J Morphol Embryol"},{"issue":"4","key":"2019_CR5","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s12253-014-9808-4","volume":"20","author":"N Michalopoulos","year":"2014","unstructured":"Michalopoulos N, Papavramidis TS, Karayannopoulou G, Pliakos I, Papavramidis ST, Kanellos I. Neuroendocrine tumors of extrahepatic biliary tract. Pathol Oncol Res. 2014;20(4):765\u201375.","journal-title":"Pathol Oncol Res"},{"issue":"2","key":"2019_CR6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.surg.2016.01.001","volume":"160","author":"K Hosoda","year":"2016","unstructured":"Hosoda K, Kobayashi A, Shimizu A, Kitagawa N, Ito T, Yamada A, et al. Neuroendocrine tumor of the common bile duct. Surgery. 2016;160(2):525\u20136.","journal-title":"Surgery"},{"issue":"3","key":"2019_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000472254","volume":"105","author":"K Oberg","year":"2017","unstructured":"Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, et al. ENETS consensus guidelines for standard of care in neuroendocrine tumours: biochemical markers. Neuroendocrinology. 2017;105(3):201\u201311.","journal-title":"Neuroendocrinology"},{"issue":"12","key":"2019_CR8","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1136\/gutjnl-2011-301748","volume":"61","author":"SA Khan","year":"2012","unstructured":"Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61(12):1657\u201369.","journal-title":"Gut"},{"issue":"9","key":"2019_CR9","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.4251\/wjgo.v12.i9.1031","volume":"12","author":"HH Wang","year":"2020","unstructured":"Wang HH, Liu ZC, Zhang G, Li LH, Li L, Meng QB, et al. Clinical characteristics and outcome of primary hepatic neuroendocrine tumors after comprehensive therapy. World J Gastrointest Oncol. 2020;12(9):1031\u201343.","journal-title":"World J Gastrointest Oncol"},{"issue":"7","key":"2019_CR10","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/dc.24173","volume":"47","author":"J Choi","year":"2019","unstructured":"Choi J, Lee KJ, Kim SH, Cho MY. Preoperative diagnosis of well-differentiated neuroendocrine tumor in common hepatic duct by brush cytology: a case report. Diagn Cytopathol. 2019;47(7):720\u20134.","journal-title":"Diagn Cytopathol"},{"issue":"1","key":"2019_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00261-014-0191-0","volume":"40","author":"N Hong","year":"2015","unstructured":"Hong N, Kim HJ, Byun JH, Kim SY, Kim KW, Kim JH, et al. Neuroendocrine neoplasms of the extrahepatic bile duct: radiologic and clinical characteristics. Abdom Imaging. 2015;40(1):181\u201391.","journal-title":"Abdom Imaging"},{"issue":"29","key":"2019_CR12","doi-asserted-by":"publisher","first-page":"e11487","DOI":"10.1097\/MD.0000000000011487","volume":"97","author":"L Zhang","year":"2018","unstructured":"Zhang L, Wan D, Bao L, Chen Q, Xie H, Xu S, et al. Neuroendocrine carcinoma in the extrahepatic biliary tract: a case report and literature review. Medicine (Baltimore). 2018;97(29):e11487.","journal-title":"Medicine (Baltimore)"},{"key":"2019_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12893-015-0116-z","volume":"15","author":"Y Kihara","year":"2015","unstructured":"Kihara Y, Yokomizo H, Urata T, Nagamine M, Hirata T. A case report of primary neuroendocrine carcinoma of the perihilar bile duct. BMC Surg. 2015;15:125.","journal-title":"BMC Surg"},{"issue":"6","key":"2019_CR14","doi-asserted-by":"publisher","first-page":"rjx104","DOI":"10.1093\/jscr\/rjx104","volume":"2017","author":"L Hoepfner","year":"2017","unstructured":"Hoepfner L, White JA. Primary extrahepatic bile duct neuroendocrine tumor with obstructive jaundice masquerading as a Klatskin tumor. J Surg Case Rep. 2017;2017(6):rjx104.","journal-title":"J Surg Case Rep"},{"issue":"1","key":"2019_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/jgh.13585","volume":"32","author":"I Sano","year":"2017","unstructured":"Sano I, Kuwatani M, Sugiura R, Kato S, Kawakubo K, Ueno T, et al. Hepatobiliary and pancreatic: a rare case of a well-differentiated neuroendocrine tumor in the bile duct with spontaneous regression diagnosed by EUS-FNA. J Gastroenterol Hepatol. 2017;32(1):11.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"2019_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/dc.24334","volume":"48","author":"M Ishida","year":"2020","unstructured":"Ishida M, Okano K, Sandoh K, Ito H, Ikeura T, Mitsuyama T, et al. Neuroendocrine carcinoma diagnosis from bile duct cytological specimens: a retrospective single-center study. Diagn Cytopathol. 2020;48(2):154\u20138.","journal-title":"Diagn Cytopathol"},{"issue":"3","key":"2019_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224\u201333.","journal-title":"N Engl J Med"},{"issue":"2","key":"2019_CR18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/CAD.0000000000000445","volume":"28","author":"E Ozaslan","year":"2017","unstructured":"Ozaslan E, Karaca H, Koca S, Sevinc A, Hacioglu B, Ozkan M, et al. Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less. Anticancer Drugs. 2017;28(2):222\u20139.","journal-title":"Anticancer Drugs"},{"issue":"2","key":"2019_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2214\/AJR.18.19953","volume":"211","author":"ES Mittra","year":"2018","unstructured":"Mittra ES. Neuroendocrine tumor therapy: (177)Lu-DOTATATE. AJR Am J Roentgenol. 2018;211(2):278\u201385.","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"2019_CR20","doi-asserted-by":"publisher","first-page":"708","DOI":"10.2967\/jnumed.115.163865","volume":"57","author":"SA Deppen","year":"2016","unstructured":"Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, et al. Safety and efficacy of 68Ga-DOTATATE PET\/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. J Nucl Med. 2016;57(5):708\u201314.","journal-title":"J Nucl Med"},{"issue":"2","key":"2019_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2214\/AJR.18.19881","volume":"211","author":"Y Sanli","year":"2018","unstructured":"Sanli Y, Garg I, Kandathil A, Kendi T, Zanetti MJB, Kuyumcu S, et al. Neuroendocrine tumor diagnosis and management: (68)Ga-DOTATATE PET\/CT. AJR Am J Roentgenol. 2018;211(2):267\u201377.","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"2019_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1586\/14737140.2016.1146135","volume":"16","author":"M Khasraw","year":"2016","unstructured":"Khasraw M, Ananda S, Michael M. Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy. Expert Rev Anticancer Ther. 2016;16(4):391\u2013401.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"12","key":"2019_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11864-020-00794-0","volume":"21","author":"N Vijayvergia","year":"2020","unstructured":"Vijayvergia N, Dasari A. Targeted therapies in the management of well-differentiated digestive and lung neuroendocrine neoplasms. Curr Treat Options Oncol. 2020;21(12):96.","journal-title":"Curr Treat Options Oncol"},{"issue":"10022","key":"2019_CR24","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. The Lancet. 2016;387(10022):968\u201377.","journal-title":"The Lancet"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-02019-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-02019-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-02019-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T09:55:37Z","timestamp":1700042137000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-02019-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,8]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2019"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-02019-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-377428\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,8]]},"assertion":[{"value":"6 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Dalian Medical University. Written informed consent was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed written consent was obtained from the patient for publication of this report and any accompanying images. A copy of the consent form is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}